| Company type | Subsidiary |
|---|---|
| Industry | Drug discovery |
| Founded | 24 February 2021  |
| Founder | Demis Hassabis |
| Headquarters | London, United Kingdom |
Key people | |
| Parent | Alphabet Inc. |
| Website | isomorphiclabs |
Isomorphic Labs Limited[1] is a London-based company which uses artificial intelligence for drug discovery.[2][3][4] Isomorphic Labs was founded by Demis Hassabis, who is the CEO.[5][3] The company was incorporated on February 24, 2021[1] and announced on November 4, 2021.[6] It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind, of which Hassabis is also founder and CEO.[2][3][7]
The company draws upon DeepMind's AlphaFold technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery.[7][8]
In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland.[7][9]
In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company to work together on AI drug discovery and research.[10]
In May 2024, Google DeepMind and Isomorphic Labs announced the release of AlphaFold 3, an artificial intelligence and foundation model platform. Available for free on the AlphaFold server for non-commercial research, the platform was developed by training it with nearly 100,000 known proteins.[11] AlphaFold 3 can predict how proteins fold and the interactions with molecules typically found in drugs such as ligands or antibodies, which is expected to significantly accelerate drug discovery.[12]
In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro[13] and CoDock[14] utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments.[15]
In April 2025, Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]
- ^ a b "ISOMORPHIC LABS LIMITED overview - Find and update company information - GOV.UK". Companies House. February 24, 2021. Retrieved August 20, 2023.
- ^ a b Shead, Sam (November 5, 2021). "Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs". CNBC. Archived from the original on November 5, 2021. Retrieved November 9, 2021.
- ^ a b c Coldewey, Devin (November 4, 2021). "Isomorphic Labs is Alphabet's play in AI drug discovery". TechCrunch. Retrieved August 23, 2022.
- ^ Crist, Ry (November 4, 2021). "Alphabet launches Isomorphic Labs, an AI-driven drug discovery startup". CNET.
- ^ Shead, Sam (November 5, 2021). "Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs". CNBC. Retrieved November 30, 2023.
- ^ Wetsman, Nicole (November 4, 2021). "Alphabet is launching a company that uses AI for drug discovery". The Verge. Retrieved September 22, 2024.
- ^ a b c Criddle, Cristina; Johnston, Ian (December 3, 2022). "DeepMind spin-off steps up effort to use AI to create new drugs". Financial Times. Archived from the original on December 5, 2022. Retrieved April 28, 2023.
- ^ Quach, Katyanna (November 8, 2021). "Alphabet launches new AI drug discovery startup, Isomorphic Labs, led by DeepMind CEO". The Register. Archived from the original on November 27, 2022. Retrieved April 28, 2023.
- ^ Aaron Hurst (December 5, 2022). "DeepMind spin-off Isomorphic Labs announces drug discovery scale plans". Information Age.
- ^ Barton, Samantha (January 8, 2024). "Alphabet's Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery". Fortune.
- ^ Dr. Sai Balasubramanian (September 10, 2024). "Google DeepMind And Isomorphic Labs Are Making Rapid Progress In Biology And Drug Discovery". Forbes.
- ^ Thomason, James (May 8, 2024). "Google's AlphaFold 3 AI predicts the very building blocks of life". VentureBeat. Retrieved May 9, 2024.
- ^ Comeau, S. R.; Gatchell, D. W.; Vajda, S.; Camacho, C. J. (July 1, 2004). "ClusPro: a fully automated algorithm for protein-protein docking". Nucleic Acids Research. 32 (Web Server): W96 – W99. doi:10.1093/nar/gkh354. ISSN 0305-1048. PMC 441492. PMID 15215358.
- ^ Kong, Ren; Liu, Ran-Ran; Xu, Xi-Ming; Zhang, Da-Wei; Xu, Xiao-Shuang; Shi, Hang; Chang, Shan (2020). "Template-based modeling and ab-initio docking using CoDock in CAPRI". Proteins: Structure, Function, and Bioinformatics. 88 (8): 1100–1109. doi:10.1002/prot.25892. ISSN 1097-0134.
- ^ "Groups Analysis: Ligand predictions - CASP16". predictioncenter.org. Retrieved December 3, 2024.
- ^ "Google-backed AI drug discovery startup raises $600 million". The Hindu. Reuters. April 1, 2025. ISSN 0971-751X. Retrieved April 1, 2025.
- ^ Merced, Michael J. de la (March 31, 2025). "Isomorphic Labs, Google's A.I. Drug Business, Raises Money From Thrive". The New York Times. ISSN 0362-4331. Retrieved April 1, 2025.